Prosecution Insights
Last updated: April 19, 2026

Examiner: HORLICK, KENNETH R

Tech Center 1600 • Art Units: 1634 1637 1677 1681

This examiner grants 79% of resolved cases

Performance Statistics

78.9%
Allow Rate
+18.9% vs TC avg
1059
Total Applications
+15.1%
Interview Lift
930
Avg Prosecution Days
Based on 1035 resolved cases, 2023–2026

Rejection Statute Breakdown

5.3%
§101 Eligibility
6.5%
§102 Novelty
38.4%
§103 Obviousness
15.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18397836 UNIVERSAL SHORT ADAPTERS WITH VARIABLE LENGTH NON-RANDOM UNIQUE MOLECULAR IDENTIFIERS Non-Final OA Illumina, Inc.
19362169 SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION Non-Final OA GUARDANT HEALTH, INC.
18544232 Methods and Systems for Detecting Biological Components Non-Final OA The Regents of the University of California
18110785 SYSTEM AND METHODS OF DETECTION OF ONCRNAS FOR CANCER DIAGNOSIS Final Rejection The Regents of the University of California
18492362 METHODS, COMPOSITIONS, AND KITS FOR BLOCKING A CAPTURE PROBE ON A SPATIAL ARRAY Non-Final OA 10x Genomics, Inc.
18029995 POLYVINYL SULFONATE DETECTION AND REMOVAL FROM BIOMOLECULE COMPOSITIONS Non-Final OA AMGEN INC.
19308103 METHODS AND SYSTEMS FOR PROCESSING CELL-FREE SAMPLES Non-Final OA CareDx, Inc.
18364809 PCR DETECTION OF SMALL FRAGMENTS OF A KNOWN NUCLEIC ACID TARGET Non-Final OA Vanderbilt University
17678357 GENE SIGNATURES FOR CANCER PROGNOSIS Final Rejection MYRIAD GENETICS, INC.
18494072 METHODS FOR FAST NUCLEIC ACID AMPLIFICATION Non-Final OA University of Utah Research Foundation
18504006 MUTATION DETECTION ASSAY Non-Final OA Exact Sciences Corporation
18545099 Nucleotide Reagent Solutions Non-Final OA LIFE TECHNOLOGIES CORPORATION
18305213 METHODS OF IDENTIFYING AND CHARACTERIZING GENE EDITING VARIATIONS IN NUCLEIC ACIDS Final Rejection PIONEER HI-BRED INTERNATIONAL, INC.
18510487 COMPOSITIONS AND METHODS FOR PAIRWISE SEQUENCING Non-Final OA Element Biosciences, Inc.
18176909 Methods of Differentiating a Malignant Tumor from a Non-Malignant Tumor Non-Final OA The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
18535790 METHODS FOR MULTIPLEX PCR Non-Final OA Integrated DNA Technologies, Inc.
18493324 FLUIDIC DEVICE AND METHODS FOR CHARACTERIZATION OF AN INFECTION OR OTHER CONDITION Non-Final OA Inflammatix, Inc.
18252684 PATHOGEN INACTIVATING AND NUCLEIC ACID STABILIZATION MEDIA FOR MICROORGANISM COLLECTION AND TRANSPORT Non-Final OA Plus Therapeutics, Inc.
18195207 ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH EXTRACELLULAR VESICLES Non-Final OA Centre for Novostics Limited
18309760 NUCLEIC ACID SEQUENCING IDENTIFYING INCORPORATED PROTECTED NUCLEOTIDES Non-Final OA 454 Corporation
18023793 METHOD FOR PREPARING TEST SOLUTION FOR PATHOGEN DETECTION PURPOSE,SYSTEM, KIT, DETECTION PRIMER AND METHOD THEREBY Non-Final OA TONGLI BIOMEDICAL CO., LTD
17773895 METHOD FOR ISOLATING NUCLEIC ACIDS Final Rejection NASASBIOTECH, S.L.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month